Donna A Volpe

List of Publications by Year
in descending order

47 papers	2,201 citations	279798 23 h-index	265206 42 g-index
50 all docs	50 docs citations	50 times ranked	3109 citing authors

#	Article	IF	Citations
1	Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regulatory Toxicology and Pharmacology, 2011, 59, 385-390.	2.7	336
2	Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients. JAMA - Journal of the American Medical Association, 2019, 321, 2082.	7.4	207
3	Variability in Caco-2 and MDCK Cell-Based Intestinal Permeability Assays. Journal of Pharmaceutical Sciences, 2008, 97, 712-725.	3.3	197
4	Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Medicinal Chemistry, 2011, 3, 2063-2077.	2.3	183
5	Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients. JAMA - Journal of the American Medical Association, 2020, 323, 256.	7.4	151
6	Permeability classification of representative fluoroquinolones by a cell culture method. AAPS PharmSci, 2004, 6, 1-6.	1.3	97
7	Application of Method Suitability for Drug Permeability Classification. AAPS Journal, 2010, 12, 670-678.	4.4	92
8	Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs. Drug Metabolism and Disposition, 2011, 39, 1196-1202.	3.3	91
9	Biopharmaceutics Classification of Selected Î²-Blockers:â€‰ Solubility and Permeability Class Membership. Molecular Pharmaceutics, 2007, 4, 608-614.	4.6	83
10	Classification of Drug Permeability with a Caco-2 Cell Monolayer Assay. Clinical Research and Regulatory Affairs, 2007, 24, 39-47.	2.1	71
11	Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Annals of Oncology, 1998, 9, 357-364.	1.2	66
12	Evaluation of transporters in drug development: Current status and contemporary issues. Advanced Drug Delivery Reviews, 2017, 116, 100-118.	13.7	62
13	Use of Different Parameters and Equations for Calculation of IC50 Values in Efflux Assays: Potential Sources of Variability in IC50 Determination. AAPS Journal, 2014, 16, 172-180.	4.4	49
14	Validation and application of a stability-indicating HPLC method for the in vitro determination of gastric and intestinal stability of venlafaxine. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1854-1859.	2.8	47
15	Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer Chemotherapy and Pharmacology, 1996, 39, 143-149.	2.3	41
16	Methadone Metabolism and Drug-Drug Interactions: InÂVitro and InÂVivo Literature Review. Journal of Pharmaceutical Sciences, 2018, 107, 2983-2991.	3.3	38
17	In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia. Cancer Chemotherapy and Pharmacology, 2018, 82, 795-802.	2.3	33
18	Advances in cell-based permeability assays to screen drugs for intestinal absorption. Expert Opinion on Drug Discovery, 2020, 15, 539-549.	5.0	33

#	Article	IF	Citations
19	Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. Journal of Experimental Therapeutics and Oncology, 2003, 3, 169-184.	0.5	29
20	Effect of uremic serum and uremic toxins on drug metabolism in human microsomes. Regulatory Toxicology and Pharmacology, 2014, 68, 297-303.	2.7	29
21	Transporter assays as useful in vitro tools in drug discovery and development. Expert Opinion on Drug Discovery, 2016, 11, 91-103.	5.0	29
22	In vitro toxicity of 3â€²â€azidoâ€3â€²â€deoxythymidine, carbovir and 2â€², 3â€²â€didehydroâ€2â€², 3â€²â€dideoxythymidine human and murine haematopoietic progenitor cells. British Journal of Haematology, 1992, 80, 437-445.	2.5	27
23	Impact of the US FDA â€œBiopharmaceutics Classification Systemâ€•(BCS) Guidance on Global Drug Development. Molecular Pharmaceutics, 2017, 14, 4334-4338.	4.6	23
24	Comparativein vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Investigational New Drugs, 1992, 10, 255-261.	2.6	19
25	Comparison of the stability of split and intact gabapentin tablets. International Journal of Pharmaceutics, 2008, 350, 65-69.	5.2	19
26	Effect of Ethanol on Opioid Drug Permeability Through Caco-2 Cell Monolayers. AAPS Journal, 2008, 10, 360-362.	4.4	18
27	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. PLoS ONE, 2020, 15, e0241362.	2.5	17
28	Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Investigational New Drugs, 1991, 9, 149-157.	2.6	16
29	Utility of Human Bone Marrow Obtained Incidental to Orthopedic Surgery for Hematopoietic Clonal Assays. Pathobiology, 1991, 59, 53-56.	3.8	13
30	Microcapillary clonogenic assays for human marrow hematopoietic progenitor cells. International Journal of Cell Cloning, 1989, 7, 303-313.	1.6	12
31	The development of biological therapies for neurological diseases: moving on from previous failures. Expert Opinion on Drug Discovery, 2018, 13, 283-293.	5.0	10
32	In vitro characterization of the myelotoxicity of cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology, 1994, 34, 103-108.	2.3	9
33	Characterization of a commercially available line of iPSC hepatocytes as models of hepatocyte function and toxicity for regulatory purposes. Journal of Pharmacological and Toxicological Methods, 2021, 110, 107083.	0.7	9
34	In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells. American Journal of Hematology, 1995, 50, 277-282.	4.1	8
35	Application of in vitro CYP and transporter assays to predict clinical drugâ€“drug interactions. Bioanalysis, 2018, 10, 619-623.	1.5	8
36	Microcapillary clonogenic assays for human marrow hematopoietic progenitor cells. International Journal of Cell Cloning, 1989, 7, 395-395.	1.6	7

#	Article	IF	Citations
37	Drug Permeability Studies in Regulatory Biowaiver Applications. , 2008, , 665-680.		7
38	Myelotoxicity of Rifabutin and 3’-Azido-3’-Deoxythymidine, Alone and in Combination, to Human Hematopoietic Progenitor Cells in vitro. Pathobiology, 1993, 61, 77-82.	3.8	5
39	In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis. Cancer Chemotherapy and Pharmacology, 2004, 54, 89-94.	2.3	3
40	Challenges with the precise prediction of ABC-transporter interactions for improved drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 697-707.	5.0	3
41	Comparison of the in vitro toxicity of 2â€²,3â€²â€dideoxynucleosides to murine hematopoietic progenitor cells. International Journal of Cell Cloning, 1992, 10, 87-93.	1.6	2
42	Effect of altered temperature storage on thein vitrocellular uptake of liposome drug products. Journal of Liposome Research, 2010, 20, 178-182.	3.3	1
43	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. , 2020, 15, e0241362.		0
44	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. , 2020, 15, e0241362.		0
45	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. , 2020, 15, e0241362.		0
46	Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. , 2020, 15, e0241362.		0
47	In vitro characterization of the myelotoxicity of cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology, 1994, 35, 182-182.	2.3	0